A new treatment option is now available on the NHS for cervical cancer that has come back or spread to other parts of the body, following our final draft guidance published today.

NICE’s healthtech guidance provided me with the perfect catalyst for change.

Teplizumab is the disease-modifying therapy for type 1 diabetes and England is the first country in Europe to recommend it's use through a health technology appraisal.

Learn how NICE's healthtech guidance is accelerating NHS adoption of a simple bowel cancer test, preventing 140,000 ...

Ectopic pregnancy and miscarriage: diagnosis and initial management NG126 17 April 2019 17 June 2026 Ectopic pregnancy and miscarriage QS69 10 September 2014 17 June 2026 ...

There is a simple discount patient access scheme for mirvetuximab soravtansine. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

Suggested remit: To appraise the clinical and cost effectiveness of teplizumab within its marketing authorisation for delaying the onset of type 1 diabetes in people aged 8 and over at risk of ...

This guideline covers recognising, diagnosing and managing attention deficit hyperactivity disorder (ADHD) in children, young people and adults. It aims to improve recognition and diagnosis, as well ...

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) BNF for Children (BNFC) Life sciences Library and knowledge services What NICE does Implementing ...

Diabetes in pregnancy: management from preconception to the postnatal period - Managing type 1 diabetes (T1D) using hybrid closed loops (update) In development GID-NG10450 Expected publication date: ...